Research programme: antibody radionucleotide conjugates - AREVA Med/Nordic Nanovector

Drug Profile

Research programme: antibody radionucleotide conjugates - AREVA Med/Nordic Nanovector

Alternative Names: Anti-CD37 212Pb-ARC - AREVA Med/Nordic Nanovector; Lead-212 conjugated anti-CD37 antibody - AREVA Med/Nordic Nanovector

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator AREVA Med; Nordic Nanovector
  • Developer AREVA Med
  • Class Antibodies; Antineoplastics; Immunoconjugates; Radiopharmaceuticals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 28 Jun 2016 Nordic Nanovector and AREVA Med enter into a research collaboration to develop lead-212 conjugated anti-CD37 antibody for Leukaemia
  • 28 Jun 2016 Preclinical trials in Leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top